(MENAFN- Swissinfo) Swiss medical community stands up for Alzheimer patients Apr 7, 2019 - 17:23 Leading Swiss medical institutions are calling for Alzheimer diagnosis and treatment to be reimbursed by compulsory health care institutions. Fifteen institutions issued a statement to that effect Sunday in a bid to counter prevailing skepticism about the existence and treatability of this disease which affects a growing number of Swiss. Alzheimer Switzerland and the Memory Center of Geneva University Hospital (HUG) are among the organisations that took this position I line with the 2014-2019 national strategy on dementia. Dementia, according to these institutions, is clearly a disease that is not part of the normal ageing process. The causes are mainly neurodegenerative or vascular. Patients, they say, have the right to receive the best treatment. "This stance, at the origin of which there has been a long reflection, was necessary for the enormous responsibility that we have towards our patients", Professor Giovanni Frisoni, director of the HUG Memory Center told Swiss news agency Keystone-SDA. It is also a question of responding to "deniers" for whom Alzheimer's is not a disease. "This minority makes a lot of noise but does not contribute in any way to the reflection on the disease and the search for therapies," regrets Frisians. In France, he notes, the costs of dementia drugs have not been reimbursed by health insurance since last year. The products Aricept, Ebixa, Exelon, Reminyl are the only ones approved and reimbursed in Switzerland. "Without them there is no alternative", stresses the professor at the HUG Memory Centre. Although these drugs do not treat Alzheimer's, they have nevertheless proved their effectiveness. They temporarily improve the condition of patients or stabilise cognitive symptoms for up to 18 months, according to the joint statement. Early diagnosis and treatment also improve people's autonomy, allowing them to live longer at home. The combination of pharmacological and non-pharmacological therapeutic approaches is necessary and is emphasised in the position paper. There are currently 151,000 people with dementia in Switzerland. Due to demographic changes, the medical community estimates 300,000 people will be affected by dementia in 2040.
MENAFN0804201902100000ID1098358407
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.